FHACT® – Our FISH-based HPV-Associated Cancer Test

Fluorescent in situ hybridization (FISH) is a sensitive and accurate technique that allows the detection of chromosome aberrations. In this method, a single-stranded fluorescent-labeled nucleic acid sequence (probe) complementary to a target genomic sequence is hybridized to metaphase chromosomes and interphase nuclei to detect the presence and absence of a given abnormality. FISH complements traditional cytogenetic karyotype analysis. The chief advantage of FISH is that is can be applied to non-dividing cells and a variety of specimen types.

CGI is developing innovative DNA-FISH probe panels dedicated to help clinicians in the clinical management and detection of HPV-associated precancer and cancers. The development and validation of these new FISH-based assays is expected to place CGI as the leader of cancer molecular diagnostics.

FISH-based HPV-Associated Cancer Test (FHACT®)

FHACT-Pipeline

The success of screening programs for the detection of precancer lesions of cervical cancer based on the appearance of abnormal cells in cytology specimens is well known, but there is a great need to identify additional biomarkers to increase the sensitivity with which precancer and cancer are detected. Given the well accepted etiologic involvement of high-risk human papillomavirus (HPV) in this disease, diagnostic assays implemented for the detection of high risk HPV types has improved the sensitivity. Genomic abnormalities observed in HPV-associated cancers can also serve as biomarkers of cancer progression, whose detection in a FISH based assay can be implemented with precancer and cancer screening programs to enhance sensitivity. The FISH-based HPV-associated Cancer Test (FHACT®) developed at CGI is a single hybridization assay for the detection of chromosomal regions often observed early in HPV-associated precancers, and as such represent biomarkers of HPV-associated cancer progression. FHACT® is anticipated to have extensive utilization in screening programs not only for cervical and anal cancers but also for other HPV-associated cancers such as oral and oropharyngeal cancers.

For more information about FHACT®, please visit www.cgifhact.com.


Discover Cancer Genetics Incorporated »

Our Research
With unparalleled excellence in oncology, our team is dedicated to empowering personalized cancer treatment.
Our Media
Stay current with the latest company news, articles, videos, and webinars.
Our Partners
CGI has established strong research collaborations with key thought leaders in oncology and major cancer centers in the U.S. and abroad.
Reports
Click here to login and view your reports.